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Abstract

The focus of this project is to produce and study the antigen-binding fragment
(Fab) of the antibody W02. W02 is a monoclonal anti-amyloid IgM that could give new
insights into the study of Alzheimer's disease. Although W02 does not bind to the
precursor proteins of an amyloid fibril, it can bind both

A~

fibrils and amyloid fibrils

formed from other proteins. Therefore, elucidating the structure of W02 could help
researchers better understand the structure of the amyloid fibrils as well W02's potential
role in passive immunotherapy and diagnosis of Alzheimer's disease (O'Nuallain and
Wetzel 2002).
To study the structure of W02, x-ray crystallography will be implemented.
However, the first challenge was to express the antibody. The yeast expression system
Pichia pastoris was chosen because it is a well understood eukaryotic system. A

eukaryotic system is useful for recombinant expression of eukaryotic proteins such as
antibodies, since bacteria often cannot fold and secrete these properly (Lange et al. 2001).
Fabs expressed in prokaryotes are often deposited within insoluble inclusion bodies,
while the yeast system can correctly oxidize and fold a heterodimeric disulfide-linked
Fab. After many failed attempts, Pichia was transformed with a recombinant plasmid
containing the W02 gene, ultimately leading to successful expression and secretion of
W02. After secretion, the antibody had to be purified. Several different protein
purification techniques were utilized, but much of the protein was lost in these steps.
Enough was purified, however, for crystallization experiments. We were able to optimize
crystallization conditions in order to produce needle-like crystals. These crystals, as well
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as the methods developed below, will further the goal of studying the structure of W02
with x-ray crystallography.

Background

Alzheimer's disease (AD) is a debilitating and tragic illness thought to be caused
by the aggregation of a nonnal peptide,

~-Amyloid (A~),

into an insoluble plaque in the

brain. There are other diseases linked to abnonnal peptide fibril and plaque fonnation,
and these are collectively referred to as "amyloidoses" (Dobson 2002).

Classic

symptoms of AD include increasing memory loss, decreasing cognitive function, and
personality change (Weiner and Frenkel 2006). AD was first described in 1906 by Dr.
Alois Alzheimer, and despite the fact that its pathology has been studied since its
discovery, there is not yet a cure (Alzheimer's Association).
There is ample evidence for

A~

as a significant pathogenic agent in AD. The

similarities between the neuropathologies of AD and Down's syndrome (Trisomy 21) are
confinned by the location of the gene for APP on chromosome 21 (Walsh and Selkoe
2007). Furthennore, in vitro and in vivo, various fonns (soluble oligomers made of 15-20
monomers, fibrillar, and

A~-derived

diffusible ligands) of

A~

peptide are toxic to

neurons (Deshpande et al. 2006), and mutations in the gene for amyloid precursor protein
(APP) and/or presenilin (a vast assembly of proteins at and within membranes that
provides the active site for y-secretase) can drastically increase the prevalence and rate of
development of AD (Walsh and Selkoe 2007).
Upon examination of the plaque deposits left in the brains of AD patients, the
secondary and tertiary structures of the peptide

A~

in plaques are different than its
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soluble form. This is understandable: modifications and conformational changes to a
normal protein could make it more susceptible to aggregation (Dobson 2002). However,
the important question is "how and why does this happen?" Knowing the pathological
mechanisms of disease can help greatly in developing therapies, and therefore much of
the current research on AD therapy is focused on understanding and interrupting these
mechanisms.
The first major pathway in AD is the initial formation of the

A~

peptide.

A~

peptide is derived from the aforementioned transmembrane protein APP, which has
neither a regular length nor a known function. APP is first cleaved by the aspartyl
protease

~-secretase (~-amyloid

cleaving enzyme-I, BACE-I) directly on the N-terminal

region of the peptide sequence that will be

A~.

A large section of APP is removed in this

cleavage reaction, but the segment of APP that contains

A~

is still anchored in the

membrane and is called C99. Another aspartyl protease, y-secretase, then cleaves three
different sites within the transmerrlbrane segment of C99, an activity which occurs within
the presenilin complex. The first section cleaved at the "€-site" is the C-terminal domain
of APP, which is released into the cytoplasm. The second section is only a six residue
long sequence cleaved at the "s-site". The third cleavage reaction releases the final

A~

peptide extracellularly, and can occur at several different sites collectively called the "y
site" (Figure I). The flexibility of this final cleavage reaction is the reason A~ peptide can
be (most commonly) 40 residues long, or two residues shorter or longer (Walsh and
Selkoe 2007) Furthermore,

A~

somehow escapes cleavage by a-secretase, a normal

enzymatic reaction which cuts the protein on the extracellular side like

~-secretase

but

closer to the membrane. This cutting releases a peptide fragment that is non-toxic; in
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other words, a-secretase cleavage of APP prevents the eventual formation of the

~40

residue long pathogenic A~ (Figure 1).

APP

Figure 1:
Action of
the aspartyl
proteases
on APP.

The pathway of formation of amyloid plaques, the self-association of A~ peptide,
is the second major process in AD. Proposing a general mechanism of this process is a
difficult task because many non-homologous peptide sequences have the ability to form
fibrils and plaques, so there appears to be no one universal mechanism of formation.
However, structural information about amyloid fibrils can give us clues as to how they
assemble. The formation of fibrils is greatly accelerated with nucleation and seeding,
similar to the process of crystallization. At some point in this process
into a

~-sheet

and stacks perpendicular to the length of the

a structure called a

"cross-~"

motif. These

cross-~

~-sheet,

A~

peptide folds

forming a strand with

strands packing together form the

fibrils of amyloid plaques (Tycko 2006).
The formation, overproduction, and buildup of

A~

peptide from APP and the

aggregation of this buildup via the mechanisms described is known as the amyloid
cascade. Currently, AD research is focused on intervening at points in this cascade, from
inhibiting

~-

and y-secretases by use of small drug compounds to immunological

approaches aimed at preventing or clearing amyloid in the brain. Immunological
approaches to AD therapy involve the use of antibody-antigen interactions. Active
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immunization involves the direct administration of some form of
triggers an immune response that creates
involves peripheral administration of

anti-A~

anti-A~

A~

peptide, which

antibodies. Passive immunization

antibodies, and both methods of

immunization have been subject to extensive experimentation and have produced
promising results (Solomon 2004).
Some passive immunological approaches to AD therapy are microglial activation,
catalytic dissolution, and the peripheral sink hypothesis, all of which describe different
ways in which monoclonal antibodies (mAbs) could be utilized to cOlnbat

A~

peptide.

Microglial activation involves antibodies binding to amyloid plaques and attracting
microglia for disposal. Catalytic dissolution uses antibodies in a somewhat different way;
in this mechanism, antibodies bind to

A~

peptide in a way that changes its conforn1ation

and act as an inhibitor to fibril formation. The peripheral sink hypothesis proposes a
much different approach than either of the two discussed. In the peripheral sink
hypothesis antibodies do not target A~ directly in the brain and spinal cord. Instead, anti
A~

antibodies bind to

A~

in the bloodstream, shifting the equilibrium between

central nervous system and

A~

in the bloodstream. By removing

A~

A~

in the

from the

bloodstream, AP is transported there from the brain to correct the imbalance and
subsequently bound by the antibody and removed (Gardberg et al. 2007). However, the
peripheral sink hypothesis is only applicable for antibodies that bind the linear epitope of
AP, and data suggests that antibodies WOl and W02 do not target this epitope (Rich and
Myszka, personal communication from Gardberg). Nonetheless, all three of these
methods require antibodies with high affinity for

A~

peptide (Gardberg et ai. 2007).
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Methods and Results

Construction and Propagation ofPiasmids

Dr. Anna Gardberg wrote a set of instructions for the creation of a plasmid
encoding a chimeric antigen-binding fragment of the antibody W02 (W02-Fab), and
these were carried out by TopGeneTech. The chimeric Fab fragment consisted of the
light chain (L) and the Fd portion of the heavy chain, and it was formed using the human
IgG constant domains and the murine variable regions. The cDNAs for the Land Fd
portion of W02 were individually cloned into the pPicZa vector using the BamHI
restriction site. Additionally, a thrombin cutting site was added to the light chain gene so
that the C-terminal His tag already in the pPicZa vector could be used. Both the L and the
Fd genes were then corrlbined into a single vector, pPicZa-W02 (pza-W02), by fusing
each in frame with the a-factor signal sequence of Saccharomyces cervisiae. The linar
order on the plasmid is 5'-AOXI promoter-alpha factor- W02 light chain (VL-CL)
Thrombin recognition sequence-6xHis tag-stop-BamHI recognition sequence-AOXI
promoter-alpha factor-W02 heavy chain (VH-CH)-stop-3'. This vector is under the
control of the AOXI promoter. The cloning was confirmed by PCR with Land Fd
specific primers, and subsequently by agarose gel electrophoresis. The plasmid was
received in a DHI0

coli stab and transformed into DH5a E. coli for propagation. The

plasmid was then purified from the DH5a culture using Wizard SV Minipreps (Promega).
The methods described above were adapted from Ning et ai. 2005 and Lange et al. 2001,
and were carried out by Dr. Anna Gardberg and TopGeneTech.
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Transformation using Pichia pastoris

Two cultures of Pichia pastor is X-33 were grown overnight in 5-10ml of YPD
media with 5ul of 100mg/ml ampicillin (for a final concentration of 100ug/ml). The
following day, the optical density of the culture as measured at 600 nm on a visible
spectrophotometer (OD600 ) was taken. From this the an10unt of yeast culture needed to
inoculate two new 100ml overnight cultures could be determined (using a doubling time
of2 hours and 10D6oo=5x107 cells/ml) with the fact that the desired OD600 would need to
be 1-2 the next day. The reasoning is as follows: 8xl0 8 cells are needed for each
transformation experiment, so if 1 OD600=5x107 cells/ml then a 100ml culture at 10D
contains 5xl09 cells total. 5x109 cells is enough to do 6.25 transformations at 8x10 8
cells/transformation. Hence, an OD6oo = 1-2 should be plenty for five transformations.
The following day, the OD600 of one of the 100ml cultures reached 1.4, although it took
much longer than expected. This OD600 translated to 7x10 9 cells (in 100ml), which was
more than enough to do five transformations.
The 100ml culture was divided into two centrifuge tubes and spun down at
1500xG for five minutes. A lithium acetate solution was prepared (lOOmM Lithium
Acetate, 0.6M sorbitol, 10mM Tris-HCI pH 7.5, and within one hour of use add 10mM
DTT), and 8ml of this solution were used per number of potential transformations (8.75
potential transformations

* 8ml = 70ml).

The two cell pellets were each resuspended in

35ml of the lithium acetate solution and allowed to incubate at room temperature for 30
minutes. These cells were then centrifuged as before, and then the cell pellets were
resuspended in 1.5ml ice cold sorbitol per number of potential transforn1ations (I.5ml
8.75

*

13ml total, or 7.5 ml per centrifuge tube.) This protocol is adapted from Wu and
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Letchworth 2004, and has a --100-fold increase in transformation efficiency over
protocols not employing the use of lithium acetate.
Prior to transformation by electroporation into yeast, the circular pPicZaA
plasmid was linearized (to be taken up effectively and efficiently by the Pichia cells.)
This was done by restriction digestion, a reaction in which an enzyme called an
endonuclease recognizes and cuts a specific nucleotide sequence within the plasmid,
causing it to open and become linear. It is important to note that the endonuclease cuts at
only one site, and furthermore does not also cut within the cloned gene of interest. Five
micrograms of purified pPicZa and pPicZa-W02 plasmids were digested with BglII and
PmeI endonucleases (both purchased as purified enzymes from New England Biolabs
(NEB)), respectively, at 37°C for 2 hours. The 40ul total-volume digest reactions were as
follows: 1) pPicZa control with BglII: 5.2ul plasmid (2.5ug), 0.5ul BglII (@ 10units/ul),
OAul 100X BSA (@ 10mg/ml), 4ul lOX NEB Buffer 3, and 29.9ul molecular biology
grade dH20; 2) pPicZa control with PmeI: 5.2ul plasmid (2.5ug), 0.5ul PmeI (@
10units/ul), OAul100X BSA (@ 10mg/ml), 4ul lOX NEB Buffer 4, and 29.9ul molecular
biology grade dH20; 3) pPicZa-W02 with BgIII: 3.8ul plasmid (l.25ug), 0.5uI BglII (@
10units/ul), OAul 100X BSA (@ 10mg/ml), 4ul lOX NEB Buffer 3, and 31.3ul molecular
biology grade dH20; 4) pPicZa-W02 with PmeI: 3.8ul 5-fold diluted plasmid (0.25ug
total), 2.0ul PmeI (@ 1un it/ul) , OAul 100X BSA (@ 10mg/ml), 4ul lOX NEB Buffer 4,
and 29.8ul molecular biology grade dH20. Reactions 1 and 2 were duplicated, 3 was
performed four times, and 4 performed 20 times. Buffers used were those recommended
and prepared by NEB (as provided with the enzymes): NEB lOx Buffer 3: 50 mM Tris
HC} (pH 7.9), 100 mM NaCI, 10 mM MgCh, I mM Dithiothreitol, NEB lOx Buffer 4:
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20 mM Tris-acetate (pH 7.9) , 50 mM potassium acetate, 10 mM Magnesium Acetate,
1 mM Dithiothreitol. Digests were confirmed using agarose gel electrophoresis using
low melting temperature 0.9% agarose and ethidium bromide staining, and a single band
at the proper molecular weight in kilobases (the plasmid is 4.96 kilobase pairs in size)
was observed. BglII worked better than PmeI in producing the digested plasmid (4.96kb).
The digested plasmid was then excised from the low-melt agarose gel and purified using
a DNA gel purification kit from Promega. The digested plasmid was eluted from the spin
column used in the Promega kit with 10 ul of molecular biology grade distilled water
(dH20; purchased from Eppendorf). The plasmid was then stored at 4C (if used the same
day) or -20C (if used the next day) until needed for yeast transformation by
electroporation.
Five experimental transformations were chosen, so five 1.5ml aliquots of the ice
cold sorbitol resuspension were transferred to 1.5ml centrifuge tubes. Each tube of cells
was pelleted and resuspended in 1.5ml ice-cold sorbitol. This wash was repeated three
times. After the final spin-down, the cell pellets were each resuspended in ice-cold
sorbitol to a total volume of 80ul. This was then transferred into 2 mnl electroporation
cuvettes (Bio-Rad) and placed on ice. The Pichia transformations performed involved the
following plasmid digests: 1) Positive control: 2ul BglII linearized pPicZa plasmid
(354nglul), 2) Positive control: 2uI PmeI linearized pPicZa plasmid (335ng/ul), 3)
Experimental: 2uI BglII linearized pPicZa-W02 plasmid (352ng/ul), 4) Experimental: 2uI
PmeI linearized pPicZa-W02 plasmid (49ng/ul), and 5) Experimental: 1ul PmeI
linearized pPicZa-W02 plasmid (49ng/ul) + 1ul ssDNA (2mg/mI). The appropriate
digested and gel-purified plasmid DNA was added to each electroporation cuvette and
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allowed to incubate on ice for five minutes. Then, each cuvette of cell-plasmid-sorbitol
mixture was electroporated using the "Pic" setting on a Bio-Rad MicroPulser
Electroporation apparatus. After electroporation, each transformation mixture was
transferred to an ice-cold eppendorftube immediately and 0.5 ml of ice-cold sorbitol was
pipetted into the mixture. The cells were allowed a 1 hour recovery at 30°C (with no
mixing or shaking). After this, 0.5 ml of YPDS rich growth media was added, and the
cells were allowed to recover for another hour (again with no mixing or shaking). After
the final recovery, each transformation was plated on YPDS agar + 200 ug/ml final
concentration of zeocin antibiotic + 50ug/ml ampicillin. While zeocin is usually lethal to

Pichia, the pPicZaA plasmid contains a gene whose protein product chemically modifies
the zeocin, rendering it ineffective. Therefore, Pichia cells which are successfully
transformed with pPicZaA-W02 plasmid are resistant to zeocin and can grow and divide
with no complications in its presence. Ampicillin has no detrimental effect on Pichia,
transformed or not, and is used to prevent bacterial contamination. Twenty ul of each of
the positive control transformations were plated, and 2ul, 20ul, 200ul, and the remaining
~ 700ul

of each of the experimental transformations were plated, each on separate YPDS

zeocin plates. The plates were incubated at 30°C, and, after two days, colonies of yeast
appeared.
Transformed colonies that had been growing in the presence of 200 ug/ml zeocin

+ 50ug/ml ampicillin were restreaked onto 1000 ug/ml zeocin + 50 ug/ml ampicillin YPD
agar plates to isolate the most resistant colonies. Theoretically, colonies that could
withstand 1000ug/ml zeocin would be synthesizing a large number of plasmids to combat
the antibiotic. By default, then, these cells would also have the capacity for generating a
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large amount of W02. Restreaked colonies that grew well and did not exhibit
contamination were then used to grow overnight cultures for Pichia DNA isolation. DNA
was isolated from each culture using colony PCR. Several colonies were treated with
zymolyase (a proprietary mixture of yeast cell membrane degrading enzymes purchased
from Zymo Research) by resuspending a colony in 10 ul of zymolyase solution (1000
units dissolved in 200 ul 0.9M sorbitol and 0.1 M Phosphate pH 7.7) and incubating for
15 min at 37°C. One ul of each of these resuspensions was used for PCR with 12.5 ul of
GoTaq Green PCR Master Mix (Promega), 2 ul each of W02-forward and -reverse
primers, and 7.5ul water. A control of 1ul zymolyase solution plus 0.2 ul 50 ng/ul
pzaW02 vector (replacing the colony resuspension) was also used. The PCR program
was a follows: 3min @ 94C (initial denaturing), 1nlin @ 94C (denaturing in cycle), 1min

@ 55C (primer-template annealing in cycle), 3min @ 72C (polymerase extension in
cycle), and 5min @ 72C (polymerase extension clean-up step. The second, third, and
fourth steps were repeated for thirty cycles. The isolated and amplified DNA was then
run on an ethidium bromide-stained 1% agarose gel. The colony "3-700A" was
determined to have the best AOX amplification as it produced dark insert bands on the
gel which matched the control, linearized pza-W02. "3-700A" (restreaked) was
subsequently used for growth and secreted expression ofW02-Fab. This re-streaking was
stored at 4C. A colony from the re-streaked "3-700A" was itself re-streaked onto YPD +
50ug/ml ampicillin + 1000ug/ml zeocin agar and incubated at 30C before growth and
expression.
The transformation was further confirmed and the methanol utilization phenotype
determined using a different colony PCR method not implementing zymolyase or
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detergent (although the zymolyase method was successful, it is expensive.) Instead of a
zymolyase solution, a colony was resuspended in 10ul of O.lN NaOH and incubated for
10 minutes at 9SoC. One ul of this was used in PCR reactions as a template with the same
PCR reagents as listed above, except AOX I-forward and -reverse primers were used
instead of W02. The methanol utilization phenotype (Mut or Mue) was verified by a
dark 1.2kb insert band on a 1010 agarose ethidium bromide stained gel indicating AOX
amplification.

Growth and Expression

The transformed Pichia pastoris cells from colony "3-700A" (restreaked) were
initially grown using the following shake-flask protocol. All cultures were grown at 28
30C, shaking at 2S0rpm. Two SOml overnight cultures were grown in BMGY + SO ug/ml
ampilcillin in 2S0ml flasks. BMGY is a yeast-rich growth media with glycerol as a
carbon additive. The next day, each overnight culture was used to inoculate 400-S00ml
BMGY in 3L flasks. Each of these cultures was grown to and OD600 of 10-11. After
reaching at least this OD600 , the cultures were each divided into four

~200ml

aliquots in

centrifuge bottles and spun down. In this system, methanol is used as the chemical
inducer of expression by activating the AOXI promoter. Each pellet was resuspended in
SOOml BMMY (the same as BMGY, except glycerol replaced by methanol) + 100ug/ml
zeocin + SOug/n11 ampicillin, and these four cultures were allowed to grow and express
for six days. To ensure continual induction of expression, each day O.S% methanol was
added to each flask.
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Seth Albright's (of the Jain Lab at the University of Tennessee) 5L fermentor
protocol was also tried. A single colony was inoculated into 100ml of YPD + 50ug/ml
ampicillin and allowed to grow at 28-30C and 250rpm for 32-48 hours (until OD> 10).
This culture was then used to inoculate 2.5L of BMGY in a 5L fermentation apparatus.
This culture was grown for 24 hours at 28C, pH 6.0 (using a 30%NH40H feed for pH
control), dissolved oxygen (DO) 30%, agitation 200-1000, and air flow 5L/min. After this
24 hour period, all the initial glycerol was exhausted as seen by'the increase in DO. The
culture was then fed 70ml of 50% glycerol plus 12mllL PTM1 metals solution (acquired
from Seth Albright; from Invitrogen's Pichia Fermentation guidelines, composed of 6.Og
cupric sulfate-5H20, 0.08g sodium iodide, 3.0g manganese sulfate, 0.2g sodium
molybdate, 0.02g boric acid, 0.5g cobalt chloride, 20.0g zinc chloride, 65.0g ferrous
sulfate-7H20, 0.2g biotin, 5ml concentrated sulfuric acid, all dissolved in 1L H20, filter
sterilized, and stored at room temperature) at 6.90/0 pump action. This glycerol feed was
tested using a DO spike test, which is performed by stopping the feed and timing a 15%
increase in DO. If the time is less than a minute, the feed is actively being used.
After the glycerol-fed batch phase, the methanol adaptation was started.
Anhydrous methanol plus 12ml/L PTMI metals solution was fed to the culture at 1.6%
pump action until the DO began to increase. The pump action was then increased to 2.3%
when a rapid DO spike occurred, and this feed continued for 14-16 hours. When the DO
again increased and renlained high and/or a rapid spike could be observed, the feed rate
was increased to 2.7% pump action. 50% antifoam/water solution was used throughout
the fermentation to decrease foaming. This rate was maintained for the remainder of the
fermentation, which was about two days. At the end of the fermentation the OD6oo was
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> 300, and the culture was removed from the flask with sterile tubing and a peristaltic
pump.

Purification
In either the shake-flask or the fermentor protocols, at the end of the expression
period each culture was centrifuged and the supernatant was vacuum filtered. The
supernatants were combined and any protein secreted into the supernatant (hopefully
including the recombinant W02-Fab) by the yeast was precipitated with 65% ammonium
sulfate. A small amount (-200ul) of supernatant untreated with ammonium sulfate was
saved and microdialyzed overnight for an SDS-PAGE gel sample; this was to ensure that
the target protein (W02-Fab) was present before continuing purification steps (Figure 2).

Note: In every gelfigure, the standard used is Bio-Rad Prestained Low Molecular Weight
Standards. The bands are, in descending order, Phosphorylase B 106, 904Da, BSA
93, 636Da, Ovalbumin 52, 264Da, Carbonic Anhydrase 37,226Da, Soybean Trypsin

Inhibitor 28, 224Da, and Lysozyme 18, 833Da. The W02-Fab is composed of the light
chain linked by disulfide bond to the Fd portion ofthe heavy chain ofthe antibody. Both
the light chain and the Fd portion weigh 25-30kDa. So, the unreduced Fab migrates to
around 50kDa on an SDS-PAGE gel, and the reduced fragments migrate and blend
together at around 30kDa. Beta-mercaptoethanol (BME) was used as a reducing agent
,~'

for all reduced gel samples. On the following gels using prestained standard, the
unreduced Fab (Light chain plus Fd) migrates near the third standard band (ovalbumin)
and the reduced Fab (Light chain and Fd separated) migrates in between the fourth and
the fifth standards (carbonic anhydrase and soybean trypsin inhibitor, respectively.)
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Molecular
Weight

Figure 2: 12% SDS-PAGE
Gel ofMicrodialyzed
Supernatants taken from the
Fermentation. Lanes: 1)
Prestained Standard, 2)
Beginning offermentation
methanol adaptation, 3) 6
hours ofmethanol
adaptation, 4) 1 day of
methanol adaptation, 5) 2
days ofmethanol adaptation,
6) vacant, 7-10) Same as
lanes 2-5, but with BME
reduced samples.
The unreduced Fab is visible
in all samples at - 50kDa, and
the reduced Fab is visible in
the last two lanes at - 30kDa.
Allfollowing gelfigures show
one or both ofthese bands.

(Jilla)

106.904
93.636

52.264

37.226

28.224

18.833

After 2+ hours of ammonium sufate precipitation, the supernatant was centrifuged
in aliquots to separate the ammonium sulfate pellet. The ammonium sulfate pellets were
then divided into smaller aliquots (0.5-3g) and the mass of each small pellet was
recorded. The ammonium sulfate pellets were stored at 4C in a wash solution of 65%
ammonium sulfate, 0.1 % sodium azide, and 1mM EDTA. Overall, about 2g of
ammonium sulfate pellet per liter of culture resulted from the fermentor (- 1Og pelletl5L),
while 1.5-2.5 g ammonium sulfate pellet per liter of culture resulted from the shake flask
protocol (-3-5g pellet/2L).
To purify the W02-Fabs from the ammonium sulfate pellets, -1-3g, or roughly
two individual pellets, was used. Each pellet was resuspended in 20mM MES (PH 6.0) to
a total volume of 2.5ml and desalted on a GE Healthcare PD-IO G25 desalting column
according to the packaged instructions. The desalted pellet resuspensions were then
subjected to further purification in one of two ways.
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The first method used to treat the desalted pellet suspensions was cation exchange
purification on a BioCad perfusion HPLC system (Perceptive Biosystems). HPLC. All
resuspended and desalted pellets were combined and brought to a 10ml load volume.
They were purified using a Poros HS column, with 20mM MES pH 6.0 used as running
buffer ("buffer A") and 20mM MES pH 6.0 + 100-250mM NaCI used as elution buffer
("buffer B"). The appropriate fractions were then analyzed using SDS-PAGE, and the
best (most pure and most highly-concentrated) fractions according to the gel were pooled
(Figures 3, 4).
m
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Figure 3: Chromatogram from Poros HS Cation Exchange Purification from 6-25-07. The HPLC
program was not correct here and stopped collecting/ractions after 96. However, this problem was
identified immediately and the peak was captured in a beaker. See corresponding SDS-PAGE gel
below.
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Figure 4: 12% SDS-PAGE Gel, 6-25-07 Poros HS Cation Exchange ofW02-Fabs (Figure 3).
Shoulder 1 isfractions 82-84, Shoulder 2 is fractions 85-87, Shoulder 3 is fractions 91-93, Peak
was collected in a small beaker. Lanes: 1) Prestained Standard, 2)Shoulder 1, 3)Shoulder 2,
4)Shoulder 3, 5)Peak, 6)Blank, 7)Shoulder 1 BME Reduced, 8)Shoulder 2 BME Reduced, 9)
Shoulder 3 BME Reduced, 1O)Peak BME Reduced The unreduced bands (2-5) show unreduced
W02-Fab (-50kDa). The reduced bands (7-10) show reduced W02-Fab (-30kDa). Both ofthese
bands are described in the note on pages 14-15.

The second method used to treat the desalted pellet suspensions was immobilized
metal affinity chromatography (IMAC), and this method worked better as a first step
(after ammonium sulfate cut) than the cation exchange. IMAC takes advantage of the Cterminal His tag in the W02-Fab construct by using metals like nickel or cobalt to
coordinate with the string of histidines. Additionally, if the cation exchange was chosen
initially but did not adequately purify the sample, IMAC was then utilized. Ni-NTA resin
(Qiagen) was used with 50mM dibasic phosphate buffer pH 8 + 300mM NaCI, and
varying imidazole concentrations for binding, wash, and elution (5, 10, and 250mM,
respectively.) Imidazole is used for elution because it competes with the His tag for metal
coordination. Each pellet solution was first brought to 100mM phosphate buffer +
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300mM NaCl. 5ml of Ni-NTA resin slurry was collected and centrifuged in a new 50ml
tube. The storage buffer was removed, and the resin was washed with 20ml of binding
buffer twice. The pellet solution sample was then added and incubated at 4C while
rocking gently for one hour. After this incubation period, the resin-protein complex was
transferred to a Bio-Rad Econocolumn of appropriate size, attached to a corresponding
flow adapter, washed on an HPLC with 10 column volumes of wash buffer. The protein
was finally eluted on a gradient (1 ~ 100%

wash~elution

buffer) over 60ml, and

collected in 1ml aliquots. According to the chromatogram, the best aliquots were chosen
and analyzed using SDS-PAGE. According to the gel, the best fractions were collected
and combined. It was subsequently dialysed into 20mM MES pH 6.0 and further purified
via cation exchange chromatography as previously described (Figures 5, 6, 7).

Figure 5: 12% SDS-PAGE gel from 7-25-07, BME reduced samples. From a Ni-NTA lMAC, 1mlfractions
collected by hand Lanes: 1) Prestained Standard, 2) Vacant 3) lMAC bindingjlowthrough, 4) lMAC wash
jlowthrough, Lanes 5-14) Fractions 1-10, respectively. Note double band only seen after fermentation.
Because this gel looked so dirty, these fractions (1-10) were combined, dialysed into 20mM MES pH6.0,
and run on a Poros HS cation exchange. That run produced a small peak which was subsequently lost in a
spill accident. The jlowthrough from this lMA C, combined with the jlowthrough from the subsequent cation
exchange were then combined and run on another cation exchange as seen below in figures 6 and 7. Note
the unidentified heavier double band above the reduced W02-Fabs at 30kDa (as previously described in
note on p. 14-15.)
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Figure 6: Chromatogram from 7-30-07: Cation Exchange 0/7-25 lMACflowthrough and 7-26 Cation
Exchange Flowthrough (from 7-25IMAC.) The 7-26 Cation Exchange was subject to an accident and all
material was lost. As this chromatogram shows, however, some protein was salvagedfrom the
flowthroughs. See corresponding gel (Figure 7).

Molecular
Weight
(kDa)

106.904
93.636

52.264

37.226

28.224

18.833

Figure 7: 12% SDS-PAGE gel 0/7-30-07 Cation Exchange (Chromatogram Figure 6). All samples were
reduced with BME. Lanes: I)Prestained Standard, 2) Vacant, 3) Flowthrough, Lanes 4-14) Odd numbered
fractions 113-133 (i.e. 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133). Note that after the Cation
Exchange, the heavier unidentified band is gone. The bands at -30kDa show reduced W02-Fab as
previously described in note on p.14-15.
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After purifying the sample via IMAC and/or cation exchange chromatography,
the sample was concentrated on a Millipore Centriplus YM-30 centrifuge filter to an
appropriate concentration (as measured by Bradford assay) for Thrombin cleavage of the
C-terminal His tag (typically> Img/ml.) A thrombin cleavage protocol was developed
based on the instructions and information in Novagen's Thrombin Kit. Novagen's lOX
Thrombin cutting buffer (200mM Tris-HCI pH 8.4, I.SM NaCI, 2SmM CaCb) was
prepared, and dilutions of thrombin were made with SO% glycerol. After testing various
concentrations of Thrombin (stock from Haematologic Technologies, Inc., -3800 NIH
U/mg, 13.6 mg/ml) and digestion times, it was determined that a four-hour digestion with
a 1:SOO thrombin dilution worked the best with our protein. The tests were scaled to SOug
protein per SOul total digestion volume, and we scaled this up to 100X (i.e. Img protein
per 1ml digestion volume) for cleaving the purified protein. Whether IMAC and cation
exchange or only cation exchange was used as described above, the thron1bin cut was
thoroughly dialyzed into 20mM MES pH 6.0 (to remove the salt from the IMAC
solutions and/or the thrombin cutting buffer) in preparation for the final purification step,
size-exclusion chromatography.
The sample was finally purified on the BioLogic HR HPLC using a Superdex 200
Column with 20mM MES pH 6.0 + 2S0mM NaCl. This method was not ideal, each time
causing SO-90% loss of protein. The protein that was left was pooled according to the
chromatogram (Figure 8) and concentrated using a Millipore YM-30 centriplus and/or a
Millipore YM-30 Centricon to S-10mg/ml (measured by Bradford assay.) The purified
W02-Fab was stored at 4C until crystallization trials.

Pridgen 22
To summarize, the purification process started with --1-3 grams of ammonium
sulfate pellet (at -l.5-2.5g ammonium sulfate pellet per liter of Pichia culture). After the
IMACICation Exchange steps the ammonium sulfate pellet yielded approximately 1-2mg
of W02-Fabs. This was used for the thrombin cut, and subsequently purified by gel
filtration on the Superdex 200 column. After this final purification step, usually less than
a milligram of protein remained for an overall yield of a few hundred micrograms of
protein produced per liter of Pichia culture. The following gel filtration chromatogram
(Figure 8) shows a purification with one of the best yields, almost 2mg of W02-Fabs per
liter of Pichia culture. This purification did not implement IMAC at all. However, when
the same protocol was repeated, much lower yields were observed-that is, these good
results could never be replicated. This is why IMAC was tried. Overall, the most
thorough and replicable purification process used IMAC, then cation exchange, then gel
filtration. Although it did not produce the highest yields, enough W02-Fabs were
purified to conduct crystallization experiments.
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l ea.

Figure 8: Final Purification Step: Size-Exclusion Chromatography on GE Superdex 200; W02, from 5-24
07. This sample had approximately 2mg ofW02-Fabs as measured by Bradford assay.

Crystallization

The W02-Fab protein was first screened for crystallization with the Quiagen
PEGS Suite and the Hampton Index screens using a Phoenix Nanodispensing Robot (Art
Robbins Instruments). The conditions that yielded crystals in these screens predominantly
contained ammonium salts, were buffered with Tris or Bis-Tris, and used varied PEGs as
a precipitant. Further optimization was carried out using a range of concentrations of
various ammonium salts, a range of pHs of Tris, Bis-Tris, and Citrate, and appropriate
concentrations (15-25%) of PEGs of polymer lengths of 3350, 6000, 8000, 10,000,
20,000 and PEG-MME5000. Many more optimizations were carried out, and the most
productive conditions usually involved an

~O.l-0.3M

ammonium salt,

~O.lM

citrate
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pH5.0, and either 25% w/v PEG3350 or PEG-MME5000. Needle crystals 400-700 x
20um were most commonly observed (Figure 9.) The most promising crystals grew in
0.3M ammonium sulfate, O.lM citric acid pH 5.0, and 25% PEG-MME 5000 via
micro seeding from a similar condition. Because X -ray diffraction experiments are usually
performed at liquid nitrogen temperatures (-180C), cryogenic buffer conditions for each
crystal condition had to be prepared and tested. The successful conditions were used to
freeze the most promising crystals in liquid nitrogen to store for later x-ray diffraction
experiments.
Figure 9: W02-Fab
Crystals, plate 141-D1.
0.2M Ammonium Sulfate,
0.1M Citric Acid pH 5. 0,
25% PEG-MME 5000.
These crystal needles are
- 4 00x5Oum. There were
crystals that were longer in
other wells, but they were
bundles ofmany very thin
crystals. These were more
separate, individually
larger, and less
aggregated.

Discussion

The methods developed and crystals produced in this project will further advance
the structure-based study of W02 and other mAbs. However, there are certainly some
aspects of the project that need refinement, most notably the expression and purification
of the protein. The project began by attempting transformation with the methods outlined
in the Invitrogen Pichia pastoris manual, but we were unable to succeed using these.
Furthermore, Pichia is known to have low transformation efficiency (Wu and Letchworth
2004). To overcome these problems, we adopted parts of the protocol reported by Wu
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and Letchworth 2004, and this worked well. Although the transformation of Pichia
pastoris was, in itself, a hard-earned success, the shake-flask preps typically only

produced a milligram or less of protein per liter of culture. This was what drove us to
consider fermentation instead of a shake-flask protocol, but the fermentation produced
similar yields. Additionally, the fermentation produced not only W02 but also what
might have been an unidentified form of W02, as seen in an extra band on SDS-PAGE
gels (Figure 5.) However, only one fermentation was attempted, and the methods
certainly need to be further studied, altered, and refined for better expression.
The major area of the project that requires refinement is the purification of the
W02-Fabs. Low levels of protein eluted in the cation exchange steps (peak absorbances
at 280nm were frequently below 0.2), but the size-exclusion chromatography steps saw
the most drastic reductions in material. Throughout the entire process,

~ 1-3g

of

ammonium sulfate cut pellet would yield a few hundred micrograms of protein at most.
Overall, the loss was primarily in the HPLC steps, and this, of course seriously limited
the number of crystallizations that could be performed.
Aside from the need for improvements to the current protocol for expressing and
purifying W02 using Pichia pastoris, the results of this project will be very useful for
further study. Using Pichia pastoris for expression of mAbs is advantageous over other
eukaryotic systems because of the fact that Pichia is well-studied, can be used for
plasmid-based recombinant gene expression, can link the mAb heterodimer and secrete it
in the correctly folded state, has relatively simple growth and expression, and provides
timely confirmation of results. Our successful transformation protocol for Pichia should
be of help to anyone wanting to use Pichia for expressing mAbs. Furthermore, both the
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successes and letdowns throughout this project provide valuable information for those
working with or planning to do similar work with Pichia. Lastly, even with the problems
of low expression and low purification yield, we did manage to purify and produce
crystals of W02-Fabs, the original goal.
The crystals produced will serve as a beginning step in x-ray crystallographic
studies of W02. Furthermore, the methods developed for producing W02 can be refined
and used for further production of W02 and other mAb crystals. I hope that the inheritors
of this project can learn from what we have done thus far and go on to accomplish much
more.

Conclusion

Research on Alzheimer's Disease is exceedingly important to a society with a
rapidly increasing elderly population. As the abilities of medicine advance, many more
people will be living into old age than in previous eras, and in the next few decades this
will be especially true of the baby-boomer generation. Diseases primarily affecting the
aged population have profound social and economic consequences, and developing
therapies for such diseases is one of our biggest challenges. Projects like the one
described here continue to address that challenge and further our understanding of
Alzheimer's Disease and potential treatments.
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Media Recipies (front Invitrogen's Pichia pastoris manual)
Yeast Extract Peptone Dextrose Medium (YPD)
1% yeast extract
2% peptone
±2% agar (for plates only)

After Autoclaving
2% dextrose (glucose)
Yeast Extract Peptone Dextrose Mediunl with Sorbitol (YPDS)
1% yeast extract
2% peptone
1M sorbitol
±2% agar (for plates only)

After autoclaving
2% dextrose (glucose)

Buffered Glycerol- or Methanol- complex Medium (BMGYIBMMY)
1% yeast extract
2% peptone
100 mM potassium phosphate, pH 6.0
] % glycerol or methanol, respectively
in nanopure or endotoxin free water

After autoclaving
] .34% yeast nitrogen base
4 x 10-5% biotin
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